These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
226 related items for PubMed ID: 32065066
1. Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound. Lamuraglia M, Barrois G, Le Guillou-Buffello D, Santin M, Kerbol A, Comperat E, Coron A, Lucidarme O, Bridal SL. Technol Cancer Res Treat; 2020; 19():1533033819886896. PubMed ID: 32065066 [Abstract] [Full Text] [Related]
2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C. Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925 [Abstract] [Full Text] [Related]
6. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments. Payen T, Dizeux A, Baldini C, Le Guillou-Buffello D, Lamuraglia M, Comperat E, Lucidarme O, Bridal SL. Ultrasound Med Biol; 2015 Aug 15; 41(8):2202-11. PubMed ID: 25980323 [Abstract] [Full Text] [Related]
7. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts. Miles KM, Seshadri M, Ciamporcero E, Adelaiye R, Gillard B, Sotomayor P, Attwood K, Shen L, Conroy D, Kuhnert F, Lalani AS, Thurston G, Pili R. PLoS One; 2014 Aug 15; 9(11):e112371. PubMed ID: 25393540 [Abstract] [Full Text] [Related]
9. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Chung C, Pherwani N. Am J Health Syst Pharm; 2013 Nov 01; 70(21):1887-96. PubMed ID: 24128964 [Abstract] [Full Text] [Related]
10. Dynamic gadobutrol-enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model. Dassler K, Scholle FD, Schütz G. Magn Reson Med; 2014 May 01; 71(5):1826-33. PubMed ID: 23754607 [Abstract] [Full Text] [Related]
15. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy. Guibal A, Taillade L, Mulé S, Comperat E, Badachi Y, Golmard JL, Le Guillou-Buffello D, Rixe O, Bridal SL, Lucidarme O. Radiology; 2010 Feb 01; 254(2):420-9. PubMed ID: 20093514 [Abstract] [Full Text] [Related]
17. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI. Zhang J, Xue W, Xu K, Yi L, Guo Y, Xie T, Tong H, Zhou B, Wang S, Li Q, Liu H, Chen X, Fang J, Zhang W. Theranostics; 2020 Feb 01; 10(16):7245-7259. PubMed ID: 32641990 [Abstract] [Full Text] [Related]